好色先生

好色先生

Explore the latest content from across our publications

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Diagnosis disclosure in multiple sclerosis: Associations with psychosocial outcomes and group-based treatment strategies
Multiple Sclerosis
P1 - Poster Session 1 (9:00 AM-5:00 PM)
341

Part I. Investigating associations of diagnosis disclosure with psychosocial outcomes in persons with multiple sclerosis (pwMS); Part II. completion of a group-based psychoeducational pilot program addressing the issue.

Individuals with MS frequently face the difficult decision of how/whether to disclose their diagnosis. Our work showed that up to 25% of pwMS actively conceal, particularly in professional settings. Higher concealment is associated with younger age, shorter disease duration, lower physical disability, and worse anxiety. Relatively little is known about the impact of concealment on psychosocial outcomes such as loneliness, social support, and self-efficacy. Treatment strategies targeting diagnosis concealment issues are needed.

Part I. Ninety pwMS completed the DISCO-MS survey, assessing concealment behavior and expected consequences of disclosure; the UCLA loneliness scale; the MS Social Support survey; the General Self-Efficacy scale; and the Self-Efficacy for Managing Chronic Diseases scale. Correlations assessed links between DISCO-MS scores and psycho-social variables. Part II. Fourteen pwMS were enrolled in in focus groups to evaluate DISCO-Talk, a structured group-based psychoeducational pilot program. Two groups (each n=7) met weekly via Zoom for 3 moderated sessions, each framed around a specific theme.

Part I. Higher concealment was associated with worse loneliness and lower social support. Higher anticipated negative consequences of disclosure were associated with worse loneliness, lower social support, and lower general and chronic disease self-efficacy. Consistently, higher anticipated positive consequences were related to lower loneliness. Part II. Completion rate was high (92.8%) as was adherence (90.4%). Qualitative participant feedback revealed that 100% found the program to be worth their time and would recommend participation to other pwMS.

Concealment is associated with loneliness and self-efficacy in pwMS. Tailored interventions addressing diagnosis concealment and its consequences are warranted.

 

Authors/Disclosures

PRESENTER
No disclosure on file
Claire Riley, MD, FAAN Dr. Riley has received personal compensation for serving as an employee of AstraZeneca. Dr. Riley has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Genentech. Dr. Riley has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for EMD Serono. Dr. Riley has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for TG Therapeutics. Dr. Riley has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Horizon. Dr. Riley has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Roche. Dr. Riley has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Amgen. Dr. Riley has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Immunic AG. Dr. Riley has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Cabaletta Bio. Dr. Riley has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Bristol Myers Squibb. Dr. Riley has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Novartis. Dr. Riley has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for TG Therapeutics.
Victoria Leavitt, PhD, FAAN (Columbia University Irving Medical Center) Dr. Leavitt has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Biogen. Dr. Leavitt has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Novartis. The institution of Dr. Leavitt has received research support from National Institutes of Health. The institution of Dr. Leavitt has received research support from National Multiple Sclerosis Society. The institution of Dr. Leavitt has received research support from Department of Defense. Dr. Leavitt has received intellectual property interests from a discovery or technology relating to health care.